Trial Profile
Fludarabine, Cyclophosphamide, and Multiple Dose Rituximab as Frontline Therapy in Chronic Lymphocytic Leukemia (CLL).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2018
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Mar 2013 Planned end date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 09 Mar 2012 Planned end date changed from 1 Nov 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.